FDA approves Portrazza to treat advanced squamous non-small cell lung cancer

Posted on November 24, 2015

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

READ MORE